I 1111111111111111 11111 lllll lllll lllll lllll 111111111111111 111111111111111111
`US00S 163 723B2
`
`c12) United States Patent
`Lulla et al.
`
`(IO) Patent No.:
`(45) Date of Patent:
`
`US 8,163,723 B2
`Apr. 24, 2012
`
`(54) COMBINATION OF AZELASTINE AND
`STEROIDS
`
`(75)
`
`Inventors: Amar Lulla, Mumbai (IN); Geena
`Malhotra, Mumbai (IN)
`
`(73) Assignee: CIPLA Limited, Mumbai (IN)
`
`( *) Notice:
`
`Subject to any disclaimer, the term ofthis
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 77 days.
`
`(21) Appl. No.: 12/879,515
`
`(22) Filed:
`
`Sep.10,2010
`
`(65)
`
`Prior Publication Data
`
`US 2010/0331289 Al
`
`Dec. 30, 2010
`
`Related U.S. Application Data
`
`(62) Division of application No. 10/518,016, filed as
`application No. PCT/GBO3/O2557 on Jun. 13, 2003.
`
`(30)
`
`Foreign Application Priority Data
`
`Jun. 14, 2002
`
`(GB) ................................... 0213739.6
`
`(51)
`
`Int. Cl.
`A61K 31155
`(2006.01)
`(52) U.S. Cl. ....................................................... 514/171
`(58) Field of Classification Search ........................ None
`See application file for complete search history.
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`2,837,464 A
`6/1958 Nobile
`3,067,197 A
`12/1962 Agnello et al.
`3,312,590 A
`4/1967 Elks et al.
`3,506,694 A
`4/1970 Oxley
`3,557,162 A
`1/1971 Voorschoten et al.
`3,639,434 A
`2/1972 Oxley et al.
`3,755,302 A
`8/1973 Ercoli et al.
`3,828,080 A
`8/1974 May et al.
`3,856,828 A
`12/1974 Phillipps et al.
`3,891,631 A
`6/1975 Phillipps et al.
`3,981,894 A
`9/1976 Phillipps et al.
`3,989,686 A
`11/1976 Phillipps et al.
`4,093,721 A
`6/1978 Phillipps et al.
`4,113,680 A
`9/1978 Karnano et al.
`4,187,301 A
`2/1980 Edwards
`4,188,385 A
`2/1980 Edwards
`4,198,403 A
`4/1980 Alvarez
`4,221,787 A
`9/1980 Bodor et al.
`4,261,984 A
`4/1981 Alvarez
`4,263,289 A
`4/1981 Edwards
`4,267,173 A
`5/1981 Draper
`4,285,937 A
`8/1981 Kalvoda
`4,310,466 A
`1/1982 Edwards
`4,335,121 A
`6/1982 Phillipps et al.
`4,377,575 A
`3/1983 Stache et al.
`4,472,393 A
`9/1984 Shapiro
`
`4,607,028 A
`4,710,495 A
`4,861,765 A
`4,992,474 A
`4,994,439 A
`4,996,335 A
`5,063,222 A
`5,081,113 A
`5,164,194 A
`5,202,316 A
`5,232,919 A
`5,271,946 A
`5,362,721 A
`5,420,120 A
`5,608,093 A
`5,658,549 A
`5,658,919 A
`5,707,984 A
`5,837,699 A
`5,849,265 A
`5,889,015 A
`5,914,122 A
`5,972,920 A
`5,981,517 A
`6,017,963 A
`6,057,307 A
`6,127,353 A
`6,136,294 A
`6,197,761 Bl
`6,261,539 Bl
`6,294,153 Bl
`6,319,513 Bl
`6,330,938 Bl
`6,391,340 Bl
`6,395,300 Bl
`6,416,743 Bl
`6,525,228 B2
`
`Schmidlin
`8/1986
`Bodor
`12/1987
`Mitsukuchi et al.
`8/1989
`Skidmore et al.
`2/1991
`Longnecker et al.
`2/1991
`Bodor
`2/1991
`Komoto eta!.
`11/1991
`Claussner et al.
`1/1992
`Hettche
`11/1992
`Claussner et al.
`4/1993
`Scheffler et al.
`8/1993
`Hettche
`12/1993
`Stache et al.
`11/1994
`Boltralik
`5/1995
`Stache et al.
`3/1997
`Akehurst et al.
`8/1997
`Ratnaraj et al.
`8/1997
`Tjoeng et al.
`1/1998
`Sequeira et al.
`11/1998
`Li-Bovet et al.
`12/1998
`Sequeira et al.
`3/1999
`Otterbeck et al.
`6/1999
`Seidel
`10/1999
`Bodor
`11/1999
`Alfonso et al.
`1/2000
`Sequeira et al.
`5/2000
`Yuen et al.
`10/2000
`Adjei et al.
`10/2000
`3/2001
`Biggadike et al.
`Adjei et al.
`7/2001
`9/2001
`Modi
`Dobrozsi
`11/2001
`12/2001
`Herve et al.
`5/2002
`Malmqvist-Granlund et al.
`5/2002
`Straub et al.
`7/2002
`Fassberg et al.
`2/2003
`Chauvin et al.
`(Continued)
`
`AU
`
`FOREIGN PATENT DOCUMENTS
`2003244799 B2
`12/2003
`(Continued)
`
`OTHER PUBLICATIONS
`
`Office Action (Final) dated Feb. 18, 2011 (23 pages), U.S. Appl. No.
`12/508,388, filed Jul. 23, 2009.
`
`(Continued)
`
`Primary Examiner -
`Johann Richter
`Assistant Examiner - Thor Nielsen
`(74) Attorney, Agent, or Firm - Conley Rose, P.C.; Rodney
`B. Carroll
`
`(57)
`
`ABSTRACT
`
`A pharmaceutical product or formulation, which comprises
`azelastine or a pharmaceutically acceptable salt, solvate or
`physiologically functional derivative thereof, and a steroid, or
`a pharmaceutical acceptable salt, solvate or physiologically
`functional derivative thereof, preferably the product or for(cid:173)
`mulation being in a form suitable for nasal or ocular admin(cid:173)
`istration.
`
`28 Claims, No Drawings
`
`

`

`U.S. PATENT DOCUMENTS
`3/2003 Biggadike et al.
`6,537,983 Bl
`6,583,180 B2
`6/2003 Link et al.
`6,787,532 B2
`9/2004 Biggadike et al.
`6,921,757 B2
`7/2005 Cuenoud et al.
`7,101,866 B2
`9/2006 Biggadike et al.
`7,244,742 B2
`7/2007 Pieper et al.
`7,776,315 B2
`8/2010 Pairet et al.
`2002/0061281 Al
`5/2002 Osbakken et al.
`2002/0076382 Al
`6/2002 Kaplan et al.
`2002/0081266 Al
`6/2002 Woolfe et al.
`2002/0103392 Al
`8/2002 Stache et al.
`2002/0165211 Al
`11/2002 Biggadike et al.
`2002/0173496 Al
`11/2002 Biggadike
`2002/0177581 Al
`11/2002 Biggadike
`2003/0018019 Al
`1/2003 Meade eta!.
`2003/0073676 Al
`4/2003 Biggadike et al.
`2003/0109511 Al
`6/2003 Biggadike et al.
`2003/0144257 Al
`7/2003 Biggadike et al.
`2003/0158163 Al
`8/2003 Cuenoud et al.
`2004/0053904 Al
`3/2004 Komoto et al.
`2004/0136918 Al
`7/2004 Garrett et al.
`2004/0204399 Al
`10/2004 Osbakken et al.
`2004/0235807 Al
`11/2004 Weinrich et al.
`2004/0242638 Al
`12/2004 Yanni et al.
`2005/0163724 Al
`7/2005 Miyadia et al.
`2005/0192261 Al
`9/2005 Jost-Price et al.
`2006/0025391 Al
`2/2006 Lulla et al.
`2006/0110331 Al
`5/2006 Dang et al.
`2006/0228306 Al
`10/2006 Lane
`2007 /0020330 Al
`1/2007 Dang et al.
`2009/0286762 Al
`11/2009 Myles et al.
`2009/0291143 Al
`11/2009 Lulla et al.
`2009/0318397 Al
`12/2009 Lulla et al.
`2010/0152147 Al
`6/2010 Fuge et al.
`
`BE
`DE
`DE
`DE
`DE
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`GB
`GB
`GB
`GB
`GB
`GB
`GB
`GB
`GB
`IL
`JP
`JP
`JP
`JP
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`
`FOREIGN PATENT DOCUMENTS
`889563 A
`11/1981
`1059906
`6/1959
`3836579 Al
`5/1989
`19947234 Al
`9/1999
`10152369 Al
`5/2002
`0004773
`10/1979
`0057401
`8/1982
`0179583
`4/1986
`0393658
`10/1990
`0416951
`3/1991
`0780127
`6/1997
`0780127 Al
`6/1997
`1519731 Bl
`4/2009
`2072051 Al
`6/2009
`1191965
`5/1970
`1296458
`11/1972
`1384372
`2/1975
`1438940
`6/1976
`1517278
`7 /1978
`2079755
`1/1982
`2088877
`6/1982
`2140800
`12/1984
`2389530 A
`12/2003
`109656
`2/1998
`04208267
`7 /1992
`8291072
`11/1996
`8291073
`11/1996
`2002-053485
`2/2002
`8903390
`4/1989
`9015816
`12/1990
`9104252
`4/1991
`9214472
`9/1992
`9531964
`11/1995
`9619199
`6/1996
`9632151
`10/1996
`9701337 Al
`1/1997
`9705136
`2/1997
`9715298
`5/1997
`9721721
`6/1997
`9721724
`6/1997
`9724365
`7 /1997
`
`US 8,163,723 B2
`Page 2
`
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`ZA
`
`9740836
`9746243 Al
`9817676
`9834596
`9848839 Al
`9901467
`9925359
`9932089
`0016814
`0033892
`0038811
`0048587
`0049993
`0066522
`0104118
`0120331
`0154481
`0154664
`0157025
`0162722
`0178736
`0178739
`0178741
`0178745
`0200199
`0200679
`0202565
`0207767
`0208243
`0212265
`0212266
`0213868
`0226723
`0236106
`02051422
`02053186
`02066422
`02070490
`02076933
`02085296
`02088167
`02100879
`03000241
`03013427
`03033000
`03035668
`03040691
`03042229
`03042230
`03048181
`03062259
`03064445
`03066033
`03066036
`03066656
`03072592
`03086399
`03105856 Al
`2004013156
`2004019955 Al
`2008012338 A2
`872389
`
`11/1997
`12/1997
`4/1998
`8/1998
`11/1998
`1/1999
`5/1999
`7 /1999
`3/2000
`6/2000
`7/2000
`8/2000
`8/2000
`11/2000
`1/2001
`3/2001
`8/2001
`8/2001
`8/2001
`8/2001
`10/2001
`10/2001
`10/2001
`10/2001
`1/2002
`1/2002
`1/2002
`1/2002
`1/2002
`2/2002
`2/2002
`2/2002
`4/2002
`5/2002
`7/2002
`7/2002
`8/2002
`9/2002
`10/2002
`10/2002
`11/2002
`12/2002
`1/2003
`2/2003
`4/2003
`5/2003
`5/2003
`5/2003
`5/2003
`6/2003
`7/2003
`8/2003
`8/2003
`8/2003
`8/2003
`9/2003
`10/2003
`12/2003
`2/2004
`3/2004
`1/2008
`4/1987
`
`OTHER PUBLICATIONS
`
`Office Action (Final) dated Feb. 24, 2011 (20 pages), U.S. Appl. No.
`12/508,393, filed Jul. 23, 2009.
`Office Action dated Feb. 16, 2011, (22 pages), U.S. Appl. No.
`10/518,016, filed Jul. 6, 2005.
`Office Action dated Sep. 30, 2010, U.S. Appl. No. 12/508,388, filed
`Jul. 23, 2009, 22 pages.
`Office Action dated Sep. 30, 2010, U.S. Appl. No. 12/508,393, filed
`Jul. 23, 2009, 31 pages.
`Schmidt, M. W., "The new topical steroid ciclesonide is effective in
`the treatment of allergic rhinitis," Journal of Clinical Pharmacology,
`1999, vol. 39, pp. 1062-1069.
`Malhotra Exhibit B, Aug. 2011.
`Maus Exhibit B, Aug. 2011.
`
`

`

`US 8,163,723 B2
`Page 3
`
`Nielsen, et al., "Intranasal corticosteroids for allergic rhinitis: supe(cid:173)
`rior relief?" Drugs, 2001, vol. 61, No. 11, pp. 1535-1691.
`Opponent's Rll6 Submission for EP1519731, 2011.
`CIPLA's response to Statement of Opposition for EPl 519731, 2011.
`Shenfield, "Fixed drug combinations: which ones can be recom(cid:173)
`mended?" Current Therapeutics, 1986, pp. 15-29.
`Opponent's Statement of Opposition for EP151973 l, 2011.
`Result of oral proceedings dated Oct. 12, 2011 of EP Patent No.
`1519731.
`Opponent's submission dated Oct. 6, 2011 to EPPatentNo. 1519731.
`Patentee's submission dated Oct. 5, 2011 to EP Patent No. 1519731.
`Patentee's submission dated Sep. 29, 2011 regarding list ofattendees
`at oral proceedings on EP Patent No. 1519731.
`Opponent's submission dated Sep. 23, 2011 regarding list of attend(cid:173)
`ees at oral proceedings on EP Patent No. 1519731.
`Opponent's submission dated Sep. 23, 2011 regarding additional
`documents on EP Patent No. 1519731.
`Patentee's submission dated Sep. 19, 2011 on EP Patent No.
`1519731.
`Patentee's response of Sep. 6, 2010 ofEP Patent No. 1519731.
`Hampel, Frank C., et al., Double-blind, placebo-controlled study of
`azelastine and fluticasone in a single nasal spray delivery device,
`Annals of Allergy, Asthma & Immunology, Aug.2010, vol. 105, pp.
`168-173.
`Biggadike, Keith, Letter to the Editor, "Fluticasone furoate/
`fluticasone propionate-different drugs with different properties,"
`The Clinical Respiratory Journal, 2011, pp. 183-184.
`Rapid response report: summary with critical appraisal, fluticasone
`furoate versus fluticasone propionate for seasonal allergic rhinitis: a
`review of the clinical and cost-effectiveness, Jun. 13, 2011,
`Fluticasone Furoate for Seasonal Allergic Rhinitis.
`Office Action dated Sep. 9, 2011 of U.S. Appl. No. 12/508,388, filed
`Jul. 23, 2009.
`Office Action dated Sep. 15, 2011 ofU.S. Appl. No. 12/508,393, filed
`Jul. 23, 2009.
`Search Report dated May 12, 2009 ofEP 09075101.
`Search Report dated May 12, 2009 ofEP 09075100.
`Mealy, N. E., et al., "Ciclesonide: treatment of allergic rhinitis
`antiallergy/antiasthmatic," Drugs of the Future, Prous Science, ES,
`vol. 26, No. 11, Nov. 2001, pp. 1033-1039.
`Office Action dated Jul. 11, 2011-20632 IL.
`Office Action dated Aug. 31, 2010 (6 pages), U.S. Appl. No.
`12/374,523, filed Jan. 21, 2009.
`Applicants' response dated Oct. 6, 2010 (8 pages) in U.S. Appl. No.
`12/374,523, filed Jan. 21, 2009.
`Office Action dated Nov. 30, 2010 (16 pages), U.S. Appl. No.
`12/374,523, filed Jan. 21, 2009.
`Applicants' response dated Feb. 24, (2010) 2011 (8 pages) in U.S.
`Appl. No. 12/374,523, filed Jan. 21, 2009.
`Office Action (Final) dated May 3, 2011 (8 pages), U.S. Appl. No.
`12/374,523, filed Jan. 21, 2009.
`Applicants' response dated Jun. 22, 2011 (9 pages) in U.S. Appl. No.
`12/374,523, filed Jan. 21, 2009.
`Notice of Non-responsive Amendment dated Jul. 6, 2011 (3 pages),
`U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
`Applicants' response dated Sep. 6, 2011 (8 pages) in U.S. Appl. No.
`12/374,523, filed Jan. 21, 2009.
`Spector, Sheldon, "Ideal pharmacotherapy for allergic rhinitis," J
`Allergy Clin Immunol, vol. 103, No. 3, Part 2, pp. S386-S387, 1999.
`Duonase Data Sheet, "The complete rhinitis control," 6 pages, Cipla
`Limited, Mumbai, India, 2004.
`Product Specification Bulletin, Avicel® RC-591, Bulletin AVC591-
`SPEC-02/09.RS, 2 pages, FMC BioPolymer, Feb. 2009.
`Product Specification Bulletin, Avicel® CL-611, Bulletin AVC61 l(cid:173)
`SPEC02/09.RS, 2 pages, FMC BioPolymer, Feb. 2009.
`File history of Brazilian Patent Application No. PI 0312128-3, 27
`pages, Apr. 2011.
`File historyofCanadian Patent Application No. 2,489,427, 19 pages,
`Dec. 2010.
`File history of Polish Patent Application No. P-373001, 95 pages,
`May 2011.
`File history of Russian Patent Application No. RU 2361593 C2, 65
`pages, Apr. 2009.
`
`Notice of Allowance dated Oct. 3, 2011 (33 pages) in U.S. Appl. No.
`10/518,016, filed Jul. 6, 2005.
`Salib, et al.; "Safety and Tolerability Profiles of Intranasal
`Anihistaminese and Intranasal Corticosteroids in the Treatment of
`Allergic Rhinitis;" Drug Safety; 2003; vol. 26, No. 12, pp. 829-911.
`Office Action dated Apr. 7, 2011 (3 pages) from counterpart applica(cid:173)
`tion, AU2009243420.
`Product Information, Nasonex®, Aug. 2001, 22 pages, Schering
`Corporation, Kenilworth, NJ, US.
`Product Specification Bulletin, Avicel® RC-591, Bulletin AVC591-
`SPEC-02/09.RS, 2 pages, FMC BioPolymer.
`Product Specification Bulletin, Avicel® CL-611, Bulletin AVC611-
`SPEC-02/09.RS, 2 pages, FMC BioPolymer.
`Ratner, Paul H., et al., "Combination therapy with azelastine hydro(cid:173)
`chloride nasal spray and fluticasone propionate nasal spray in the
`treatment of patients with seasonal allergic rhinitis," Annals of
`Allergy, Asthma & Immunology, Jan. 2008, vol. 100, Cover page,
`publishing page, pp. 74-81.
`Ratner, Paul H., et al., "A Comparison of the Efficacy ofFluticasone
`Propionate Aqueous Nasal Spray and Loratadine, Alone and in Com(cid:173)
`bination, for the Treatment of Seasonal Allergic Rhinitis," The Jour(cid:173)
`nal of Family Practice, Aug. 1998, vol. 47, No. 2, pp. 118-125,
`Appleton & Lange.
`Reddy, Indra K., ed., "Ocular Therapeutics and Drug Delivery: A
`Multi-Disciplinary Approach," 1996, pp. 382-385 plus cover page
`and publication page, Technomic Publishing Company, Inc.
`Safety Data Sheet, SDS No. 110556, Jul.4, 2008, Vl4, FlonaseNasal
`Spray, 5 pages, GlaxoSmithKline.
`Safety Data Sheet, SDS No. 110536, Jun. 23, 2008, Vl3, Beconase
`Hayfever Allergy Spray, 5 pages, GlaxoSmithKline.
`Salib Rarni Jean, et al., "Safety and Tolerability Profiles oflntranasal
`Antihistamines and Intranasal Corticosteroids in the Treatment of
`Allergic Rhinitis," Drug Safety 2003, vol. 26, No. 12, Cover page,
`publication page, pp. 863-893, ADIS Data Information BV.
`Simpson, Richard J., "Budesonide and terfenadine, separately and in
`combination, in the treatment of hay fever," Annals of Allergy, Dec.
`1994, vol. 73, Cover page, publication page, pp. 497-502.
`Spector, Sheldon, "Ideal pharmacotherapy for allergic rhinitis," J
`Allergy Clin Immunol, 1999, vol. 103, No. 3, Part 2, pp. S386-S387,
`Mosby, Inc ..
`Wang, De-Yun, "Treatment of Allergic Rhinitis: HI-Antihistamines
`and Intranasal Steroids," Current Drug Targets-Inflammation &
`Allergy, 2002, vol. I, pp. 215-220, Bentham Science Publishers Ltd.
`Wiseman, Lynda R., et al., "Intranasal Fluticasone Propionate: A
`Reappraisal of its Pharmacology and Clinical Efficacy in the Treat(cid:173)
`ment of Rhinitis," Drugs, 1997, vol. 53, No. 5, pp. 885-907, Adis
`International Limited.
`World Review 2001: The Pharmaceutical Market, vol. 1 Interna(cid:173)
`tional, IMC Health, 2001, cover, preface, and copyright pages plus
`pp. 4-42 and 5-1 through 5-11, IMS A.G.
`Applicant Response to foreign communication EP Patent 1519731,
`Aug. 11, 2011, 252 pages.
`"Azelastine," STN Registry No. 58581-89-8, STN Registry File,
`Retrieved Nov. 23, 2010, p. 1.
`"Fluticasone Furoate," STN Registry No. 397864-44-7, STN Regis(cid:173)
`try File, Retrieved Nov. 23, 2010, p. 1.
`Astepro ( azelastine HCI) Nasal Spray O .15%, Meda Pharmaceuticals
`Inc., 2009, Press Release, pp. 1-4.
`Aigbirhio, Franklin I., et al., "Automated radiosynthesis of no-car(cid:173)
`rier-added
`[S-fluoromethyl-18F]Fluticasone propionate as a
`radiotracer for lung deposition studies with PET," Journal of Labelled
`Compounds and Radiopharmaceuticals, vol. 39, No. 7, 1997, pp.
`569-584.
`Austin, et al., "Mometasone furoate is a less specific glucocorticoid
`than fluticasone propionate," Eur. Respir. J., 2002, vol. 20, pp. 1386-
`1392.
`Banov, et al., "Once daily intranasal fluticasone propionate is effec(cid:173)
`tive for perennial allergic rhinitis," Annals of Allergy, 1994, vol. 73,
`pp. 240-246.
`Baumgarten, C., et al., "Initial treatment of symptomatic mild to
`moderate bronchial asthma with
`the
`salmeterol/fluticasone
`propionate (50/250µg) combination product (SAS 40023)," Euro(cid:173)
`pean Journal of Medical Research, 2002, vol. 7, pp. 1-7.
`
`

`

`US 8,163,723 B2
`Page 4
`
`Berstein, et al., "Treatment with intranasal fluticasone propionate
`significantly improves ocular symptons in patients with seasonal
`allergic rhinitis," Clin. Exp. Allergy, 2004, vol. 34, pp. 952-957.
`Brooks, et al., "Spectrum of seasonal allergic rhinitis symptom relief
`with topical corticoid and oral antihistamine given singly or in com(cid:173)
`bination," American Journal ofRhinology, 1996, vol. 10, No. 3, pp.
`193-199.
`Bryson, et al., "Intranasal fluticasone propionate: a review of its
`pharmacodynamic and pharmacokinetic properties, and therapeutic
`potential in allergic rhinitis," Drugs, 1992, vol. 43, No. 5, pp. 760-
`775.
`Busse, William, et al., "Steroid-sparing effects of fluticasone
`propionate 1 00µg and salmeterol 50 µg administered twice daily in a
`single product in patients previously controlled with fluticasone
`propionate 250 µg administered twice daily," J. Allergy Clin.
`Immunol., vol. 111, No. 1, Jan. 2003, pp. 57-65.
`CAS Registry No. 102113-40-6, 2004.
`CAS Registry No. 90566-53-3, "Fluticasone," Nov. 16, 1984.
`Chapman, et al., "Anti-inflammatory activity of inhaled mometasone
`furoate in allergic mice," Arzneimettelforschung ("Drug Research"),
`1998, vol. 48, No. 4, pp. 384-391.
`Daley-Yates, et al., "Systemic bioavailability of fluticasone
`propionate administered as nasal drops and aqueous nasal spray
`formulations," Br. J. Clin. Pharmocol., 2001, vol. 51, pp. 103-105.
`Derby, et al., "Risk of cataract among users of intranasal
`corticosteroids," J. Allergy Clin. Immunol., 2000, vol. 105, No. 5, pp.
`912-916.
`Dewester, et al., "The efficacy of intranasal fluticasone propionate in
`relief of ocular symptoms associated with seasonal rhinitis," Allergy
`and Asthma Proc., 2003, vol. 24, No. 5, pp. 331-337.
`Dictionary of Organic Compounds, 6th Ed., vol. 1, p. 3234, definition
`of"fluticasone," Chapman & Hall, 1996.
`Do Jovich, et al., "Multicenter trial offluticasone propionate aqueous
`nasal spray in ragweed allergic rhinitis," Annals of Allergy, 1994, vol.
`73, No. 2, pp. 147-153.
`Fowler, Stephen J., et al., "Step-down therapy with low-dose
`fluticasone-salmeterol
`combination
`or
`medium-dose
`hydrofluoroalkane 134a-beclomethasone alone," J. Allergy Clin.
`Immunol., vol. 109, No. 6, Jun. 2002, pp. 929-935.
`Garner, R. C., et al., "A validation study comparing accelerator MS
`and liquid scintillation counting for analysis of 14C-labelled drugs in
`plasma, urine and faecal extracts," Journal of Pharmaceutical and
`Biomedical Analysis, vol. 24, 2000, pp. 197-209.
`Gawchik, et al., "Comparison of intranasal triamcinolone acetonide
`with oral loratadine in the treatment of seasonal ragweed-induced
`allergic rhinitis," Am. J. Man. Care, 1997, vol. 3, No. 7, pp. 1052-
`1058.
`Harding, "The human pharmacology of fluticasone propionate," Res(cid:173)
`piratory Medicine, 1990, vol. 84, Suppl. A, pp. 25-29.
`Howland, "Fluticasone propionate: topical or systemic effects?"
`Clinical and Experimental Allergy, 1996, vol. 26, Suppl. 3, pp. 18-22.
`Isogai, et al., "Binding affinities of mometasone furoate and related
`compounds including its metabolites for the glucocorticoid receptor
`of rat skin tissue," J. Steroid Biochem. Mo!. Biol., 1993, vol. 44, pp.
`141-145.
`Johansson, Gunnar, et al., "Comparison of salmeterol/fluticasone
`propionate combination with budesonide in patients with mild-to(cid:173)
`moderate asthma," Clin. Drug Invest., vol. 21, No. 9, 2001, pp.
`633-642, 11 pages.
`Juniper, Elizabeth F., et al., "Impact of inhaled salmeterol/fluticasone
`propionate combination product versus budesonide on the health(cid:173)
`related quality of life of patients with asthma," Am. J. Respir. Med.,
`vol. 1, No. 6, 2002, pp. 435-440.
`Kenley, Richard A., et al., "An automated, colunm-switching HPLC
`method for analyzing active and excipient materials in both cream
`and ointment formulations," Drug Development and Industrial Phar(cid:173)
`macy, vol. 11 (9 & 10), 1985, pp. 1781-1796.
`Kertesz, Denis J., et al., "Thiol esters from steroid 17!3-carboxylic
`acids: carboxylate activation and internal participation by 17
`a-acylates," J. Org. Chem., vol. 51, 1986, 14 pages.
`Kooreman, et al., "The synthesis of 17-esters of corticosteroids pro(cid:173)
`tection of 1113-hydroxyl of the trimethylsilyl group," Synthetic Com(cid:173)
`munications, vol. 1, No. 2, pp. 81-87, 1971.
`
`Laforce, et al., "Fluticasone propionate: an effective alternative treat(cid:173)
`ment for seasonal allergic rhinitis in adults and adolescents," J. Fam.
`Pract., 1994, vol. 38, No. 2, pp. 145-152.
`Lane, S.
`J.,
`et
`al.,
`"Evaluation of a new
`capillary
`electrochrornatography/rnass spectrometry interface using short col(cid:173)
`umns and high field strengths for rapid and efficient analyses," Rapid
`Communications in Mass Spectrometry, vol. 10, 1996, pp. 733-736.
`Lewis, Sarah A., et al., "Association of specific allergen sensitization
`with socioeconomic factors and allergic disease in a population of
`Boston women," J. Allergy Clin. Immunol., vol. 107, No. 4, Apr.
`2001, pp. 615-622.
`Li, et al., "Synthesis of aryl 5-(2-chlorophenyl)-2-furoates under
`phase transfer catalysis," Synthetic Communications, vol. 32, No. 20,
`pp. 3081-3086, 2002.
`Linder, "Symptom scores as measurements of the severity of
`rhinitis," Clinical Allergy, 1988, vol. 18, pp. 29-37.
`Lutsky, et al., "A novel class of potent topical antiinflammatory
`agents: 17-benzolyated, 7a-halogeno substituted corticosteroids,"
`Arzneimettelforschung ("Drug Research"), 1978, vol. 29, No. 11, pp.
`1662-1667.
`Lyseng-Williamson, Katherine A., et al., "Inhaled salmeterol/
`fluticasone propionate combination in chronic obstructive pulmo(cid:173)
`nary disease," Am. J. Respir. Med., vol. 1, No. 4, 2002, pp. 273-282.
`Mahoney, Janette M., et al., "Drug effects on the neovascularization
`response to silver nitrate cauterization of the rat cornea," Current Eye
`Research, vol. 4, No. 5, 1985, pp. 531-535.
`Millard, Jeffrey W., et al., "Solubilization by cosolvents establishing
`the log-linear model," Int'! Journal of
`useful constants for
`Pharmeceutics, vol. 245, 2002, pp. 153-166.
`Mistry, Nisha, et al., "Characterisation of impurities in bulk drug
`batches of fluticasone propionate using directly coupled HPLC(cid:173)
`NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and
`Biomedical Analysis, vol. 16, 1997, pp. 697-705.
`Mistry, Nisha, et al., "Impurity profiling in bulk pharmaceutical
`batches using 19F NMR spectroscopy and distinction between
`monomeric and dimeric impurities by NMR-based diffusion mea(cid:173)
`surements," Journal of Pharmaceutical and Biomedical Analysis, vol.
`19, 1999, pp. 511-517.
`Moreno-Vargas, et al., "Synthesis and gylcosidase inhibitory activi(cid:173)
`ties of 5-( l' ,4'-dideoxy-1' ,4'-imino-D-erythrosyl)-2-methyl-3-furoic
`acid
`(~5-[(3S,4R)-3,4-dihydroxypyrrolidin-2-yl]-2methylfuran-3-
`carboxylic acid) derivatives: new leads as selective alpha-L(cid:173)
`fucosidase and beta-galactosidase inhibitors," Helvetica Chimica
`Acta, vol. 86, pp. 1894-1913, 2003.
`Nathan, et al., "A once daily fluticasone proprionate aqueous nasal
`spray is an effective treatment for seasonal allergic rhinitis," Annals
`of Allergy, 1991, vol. 67, pp. 332-338.
`Nelson, Harold, S., et al., Fluticasone propionate-salmeterol combi(cid:173)
`nation provides more effective asthma control than low-dose inhaled
`corticosteroid plus montelukast, J. Allergy Clin. Immunol., vol. 106,
`No. 6, Dec. 2000, pp. 1088-1095.
`Ong, John T. H., et al., "Micellar solubilization oftimobesone acetate
`in aqueous and aqueous propylene glycol solutions of nonionic
`surfactants," Pharmaceutical Research, vol. 5, No. 11, 1988, pp.
`704-708.
`Ong, John T. H., et al., "Intrinsic potencies of novel thiol ester
`corticosteroids RS-85095 and RS-21314 as compared with
`clobetasol 17-propionate and fluocinonide," Arch Dermatol, vol.
`125, Dec. 1989, pp. 1662-1665.
`Onrust, et al., "Mometasone furoate, a review of its intranasal use in
`allergic rhinitis," Drugs, vol. 56, No. 4, Oct. 1998, pp. 725-745, vol.
`21.
`Pettersson, Berti!, et al., "Re-evaluation of the classical mycoplasma
`lipophilum cluster (Weisburg, et al., 1989) and description of two
`new clusters in the hominis group based on 16S rDNA sequences,"
`Int'! Journal of Systematic & Evolutionary Microbiology, 2001, vol.
`51, pp. 633-643.
`Phillips, G. H., et al., "Synthesis and structure activity relationships
`in a series of anti-inflammatory corticosteroid analogues, halomethyl
`androstane-l 7B-carbothioates and-l 7B-carboselenoates," Jour(cid:173)
`nal of Medicinal Chemistry, 1994, vol. 37, pp. 3717-3729.
`Product Information Flonase (Fluticasone proprionate) Nasal Spray
`50 mcg, 2004, pp. 1-13.
`
`

`

`US 8,163,723 B2
`Page 5
`
`Product Information Rhinocort Aqua (budesonide) Nasal Spray 32
`mcg, 2005, pp. 1-2.
`Sakagami, et al., "Mucoadhexive BDP microspheres for powder
`inhalation-their unique pharmacokinetic-pharmacodynamic pro(cid:173)
`files," Respiratory Drug Delivery, vol. VI, pp. 193-199, 1998.
`Sandham, et al., "Synthesis and biological properties of novel
`glucocorticoid androstene C-17 furoate esters," Bioorganic &
`Medicinal Chemistry, 2004, vol. 12, pp. 5213-5224.
`Scadding, et al., "Clinical and physiological effects of fluticasone
`propionate aqueous nasal spray in the treatment of perennial rhinitis,"
`Rhinology, 1991, Suppl. 11, pp. 37-43.
`Settipane, et al., "Triamcinolone acetonide aqueous nasal spray in
`patients with seasonal ragweed allergic rhinitis: a placebo-controlled,
`double-blind study," Clin. Ther., 1995, vol. 17, No. 2, pp. 252-263.
`Shapiro, et al., "17-esters and 17,21-diesters of 9-alpha, 11-beta(cid:173)
`dichlorocorticoids. Synthesis and anti-inflammatory activity," Ste(cid:173)
`roids, vol. 9, No. 2, pp. 143-156, 1967.
`Shapiro, et al., "Synthesis and structure-activity studies of
`corticosteroid 17-heterocyclic aromatic esters. 1. 9-alpha, 11-beta
`dichloro series," Journal of Medicinal Chemistry, vol. 30, No. 6, pp.
`1068-1073, 1987.
`Shapiro, et al., "17 heteroaroyl esters of corticosteroids 2. 11 beta
`hydroxy series," Journal of Medicinal Chemistry, American Chemi(cid:173)
`cal Society, Washington, US, vol. 30, No. 9, 1987, pp. 1581-1588.
`Smith, et al., "In vitro glucocorticoid receptor binding and transcrip(cid:173)
`by
`topically
`active
`glucocorticoids,"
`tional
`actJv1atJon
`Arzneimettelforschung, 1998, 48(II)(9), pp. 956-959.
`Smith, N., et al., "Comparison of the electroosmotic flow profiles and
`of
`stationary
`phases
`used
`in
`capillary
`selectivity
`electrochromatography," Journal of Chromatography A., vol. 832,
`1999, pp. 41-54.
`Souness, et al., "Immunosuppressive and anti-inflammatory effects
`of cyclic AMP phosphodiesterase (PDE) type 4
`inhibitors,"
`Immunopharmacology, 2000, vol. 47, Nos. 2/3, pp. 127-162.
`Stempel, et al., "Treatment of allergic rhinitis: an evidence-based
`evaluation of nasal corticosteroids versus nonsedating antihista(cid:173)
`mines," Am. J. Man. Care, 1998, vol. 4, pp. 89-96.
`Study No. 03DMW062-"Pharmacokinetics of GW685698X and
`CCl 18781 (fluticasone propionate) when co-administered by the
`intratracheal or intravenous route to the anaesthetised white pig,"
`2004.
`Study No. B30947-"The Pharmacokinetics of GW685698X and
`CCl 18781
`following
`intratracheal co-administration
`to
`the
`anaesthetised white pig," 2003.
`Szefler, Stanley J., et al., Chapter 21, "Glucocorticoids in severe
`asthma: mechanisms of action and route of administration," Difficult
`Asthma, pp. 371-375, Martin Dunitz Ltd., Informa Health Care,
`1999.
`Togashi, et al., 9-fluoro-llB, 17, 21-trihyrdroxy-16a-methyl-l,4-
`pregnadiene-3,
`20-dione
`21-cyclohexanecarboxylate
`17-cyclopropanecarboxylate (ST126); Oyo Yakuri, 2002, vol. 63,
`No. 5/6, pp. 61-77.
`Undem, et al., "Neural integration and allergic disease," J. Allergy
`Clin. Immunol., 2000, vol. 106, No. 5, pp. S213-S220.
`The United States Pharmacopoeia, 23rd Ed., US Pharmacopoeia
`Convention, Inc., Rockville MD, 1995, pp. 1843-1844, "Physical
`Tests / (941) X-Ray Diffraction."
`Van AS, et al., "Once daily flluticasone propionate is as effective for
`perennial allergic
`rhinitis as
`twice daily beclomethasone
`dipropionate," J. Allergy Clin. Immunol., 1993, vol. 91, No. 6, pp.
`1146-1154.
`Van Bavel, et al., "Ocular efficacy and clinician overall evaluation of
`intranasal fluticasone proprionate (FP) versus loratadine (LOR) in
`seasonal allergic rhinitis (SAR)," Annals of Allergy, Asthma, &
`Immunology, 1997, vol. 78, p. 128, Abstract Pl 01.
`Wenkert, et al., "Short syntheses offuran and catechol derivatives. A
`synthesis ofhydrourushioll ,2," Journal American Chemical Society,
`vol. 105, pp. 2021-2029, 1983.
`Westlund, et al., "Fluticasone propionate aqueous nasal spray 200 mg
`once daily provides relief of ocular symptoms associated with sea(cid:173)
`sonal allergic rhinitis," 57th Annual Meeting of the American Acad(cid:173)
`emy of Allergy, Asthma and Immunology, New Orleans LA, Mar.
`16-21, 2001, Abstract No. 522.
`
`Woodford, et al., "Activity and bioavailability of a new steroid
`(Timobesone acetate) in cream and ointment compared with Lidex
`and Dermovate creams and ointments and Betnovate cream," Int'!
`Journal of Pharmaceutics, 1985, vol. 26, pp. 145-155.
`Observations on patentability of the object of the patent application
`PV 2003-352 (Czech Republic), 2003.
`Notice of Opposition to the grant of patent on Patent Application No.
`762/2001 (140397) (Pakistan), 2010.
`CIPLA Annual Report Extract; 2010; (report shows that they
`launched an FF+azelastine product in 2010).
`Declaration of Geena Malhotra for EP151973 l dated Aug. 11, 2011.
`Declaration of Joachim Maus for EP151973 l dated Aug. 10, 2011.
`Vanrell, "Preservatives in ophthalmic formulations: an overview,"
`Arch. Soc. Esp. Oftalmol., 2007, vol. 82, pp. 531-532.
`Malhotra Exhibit A, Aug. 2011.
`ABPI Data Sheet Compendium, 1995-96, cover page plus pp. 38-39,
`Datapharm Publications Limited, London, Great Britain.
`Akerlund, Anders, et al., "Clinical trial design, nasal allergen chal(cid:173)
`lenge models, and considerations of relevance to pediatrics, nasal
`polyposis, and different classes of medication," J. Allergy Clin.
`Immunol., Mar. 2005, vol. 115, No. 3, pp. S460-S482.
`Applicants response
`to
`foreign communication-KRl0-2004-
`7020819, Dec. 27, 2010, 18 pages.
`Applicants response to foreign communication-EP 03738280.1
`(EP Patent 1519731), Sep. 6, 2010, 15 pages.
`Applicants response to foreign communication----CA 2489427, Dec.
`20, 2010, 10 pages.
`Avicel® RC/CL, Microcrystalline Cellulose and Carboxymethylcel(cid:173)
`lulose Sodium, NF Dispersible Cellulose, BP, Specifications and
`Analytical Methods, RC-16 Updated Oct. 1995 (Feb. 1999), 6 pages,
`FMC BioPolymer.
`Opposition to EP 1518731, Aug. 8, 2011, 19 pages.
`Aurora, Jack, "Nasal Delivery; Development of Nasal Delivery Sys(cid:173)
`tems: A Review," Drug Delivery Technology, vol. 2, No. 7, Oct. 2002,
`8 pages, http://www.drugdelivelytech.com/ME2/Segments/Publica(cid:173)
`tions: Article&id~9EB19EB2F29F462089CE081473F5F3CA.
`Baena-Cagnani, Carlos E., "Safety and Tolerability of Treatments for
`Allergic Rhinitis in Children," Drug Safety 2004, vol. 27, No. 12, pp.
`883-898, ADIS Data Information BV.
`Barnes, M. L., et al., "Effects of levocetirizine as add-on therapy to
`fluticasone in seasonal allergic rhinitis," Clinical and Experimental
`Allergy, Jan. 27, 2006, vol. 36, pp. 676-684, Blackwell Publishing
`Ltd.
`Berge, Stephen M., et al., "Pharmaceutical Salts," Journal of Phar(cid:173)
`maceutical Sciences, vol. 66, No. 1, Jan. 1977, pp. 1-19.
`Block, John H., et al., "Inorganic Medicinal and Pharmaceutical
`Chemistry," 1986, cover, publication, and preface pages plus p. 100,
`Indian Edition, Varghese Publishing House, Bombay, India.
`Cipla Sixty-Ninth Annual Report 2004-2005, cover pages, informa(cid:173)
`tion page, plus pp. 3, 5, and 44.
`Di Lorenzo, G., et al., "Randomized Placebo-controlled Trial Com(cid:173)
`paring fluticasone aqueous nasal spray in mono-therapy, fluticasone
`